At Welala, we are deeply committed to improving patient outcomes in the fight against cancer. We are honored to share the inspiring story of Dr. Kakanan Teinchai (Oncologist) and how our Onco-PDO technology is helping to provide better care for patients. Join us in our mission to improve cancer care. Watch Dr. Kakanan Teinchai's inspiring testimonial to learn how Welala's Onco-PDO technology is making a difference. Together, we can improve patient lives.
Hear from the oncologist "Revolutionizing Cancer Treatment: Oncologists Share Their Insights on Patient-Derived Organoids" A brighter future for cancer patients: Patient-derived organoids represent a significant step forward in the fight against cancer. By harnessing the power of this technology, we can bring hope to countless patients and their families. Hear from the oncologist (Dr.Kakanan Teinchai): "Patient-derived organoids have been a game-changer in my practice. They allow me to provide more personalized and effective care for my patients with advanced cancers." "This technology is giving us unprecedented insights into the complexities of cancer. We can now tailor treatment plans with a level of precision never before possible." “Wouldn't it be better if we could know in advance which cancer we have responds best to which drug, without having to give the drug first and wait to see if the cancer responds well? For example, in advanced pancreatic cancer, which is considered another cancer that is difficult to treat because the disease itself is quite aggressive, there are still relatively few drugs used for treatment. The main principle is to use chemotherapy. There are two main formulas for chemotherapy, so when a patient is resistant to both the first formula and the second formula. Then, the question is, what should the patient get the third formula? Right now, there is still relatively little information. So, wouldn't it be better if we could test the drug-resistant cancer cells in a test tube before injecting them into the patient? Because if we choose a drug and the disease does not respond to treatment, the patient may not have a second chance to give the next formula. For example, this patient of mine has advanced pancreatic cancer. He has been given both main formulas and is resistant to both formula. So, I sent them for a test called PDO or Patient-Derived Organoid, which is the cultivation of cells in a test tube and finding the optimal drug that the cancer responds the best. We will see that the results report will tell us which drug formula the patient responds to the best and choose that formula. We will see that the treatment results are very good. If we choose the drug formula according to the drug's sense in the result report, we will see that the liver lump has greatly reduced and the patient has returned to having a better quality of life as before.” #cancer #organoids #precisionmedicine #oncology #healthcare Credit : dr.tarnfightcancer Dr.Tarn หมอตาลต้านมะเร็ง https://lnkd.in/g4C8-fKE https://lnkd.in/gBbPWRWX